NEW YORK,, November 23, 2022 /PRNewswire/ — Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Equillium, Inc. (“Equillium” or the “Company”) (NASDAQ : EQ), in its acquisition of Metacrine, Inc. (Metacrine) (NASDAQ: MTCR). Under the terms of the merger agreement, Equillium will issue shares valued at a 25% premium to Metacrine’s net cash delivered at closing, which is estimated to be approximately $26 million.
If you own Equillium actions and wish to discuss this survey or have questions about this notice or your rights or interests, visit our website:
Or please contact:
Joshua Rubin, Esq.
305 Broadway, 7e Floor
New York, NY 10007
Weiss Law is investigating whether (i) Equillium’s Board of Directors acted in the best interests of the Company’s shareholders in agreeing to the merger and (ii) all information regarding the sale process and assessment of the transaction will be fully and fairly disclosed.
Weiss Law has litigated hundreds of shareholder class and derivative actions for breach of corporate and fiduciary duties. We’ve recovered over $1 billion for defrauded customers and won significant corporate governance relief in many of those cases. If you have information or want legal advice regarding possible corporate wrongdoing (including insider trading, waste of company assets, accounting fraud or misleading information), fraud consumer rights (including false advertising, defective products or other deceptive marketing practices), or anti-trust violations, please email us at [email protected]
SOURCE Weiss’ Law